RxDoctor Payments Data

Vitia Pack, PA

Physician Assistant · Marietta, GANPI 1013133826

Payments from drug & device makers

$960in general payments, 2019–2025

Across 29 payments — averaging $33.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$213
  • Lilly USA, LLC$192
  • Exact Sciences$182
  • Esperion Therapeutics, Inc.$125
  • AstraZeneca$108
  • AbbVie$37
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$960100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$960 in reported general payments places this provider in the 65th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$14,517
Medicare patients
50
Services billed
319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$31,359
OzempicSemaglutide16$22,475
EntrestoSacubitril/Valsartan16$13,817
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,744
Tresiba Flextouch U-200Insulin Degludec13$7,454
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,269
SynthroidLevothyroxine Sodium17$1,401
Albuterol Sulfate HfaAlbuterol Sulfate21$1,041
Amlodipine Besylate128$1,027
Atorvastatin Calcium114$979
Rosuvastatin Calcium78$975
Fluticasone Propionate80$893
Potassium Chloride38$884
Levothyroxine Sodium61$871
Losartan Potassium90$824

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$213$22,47516 claims
AbbVieSynthroid$37$1,40117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →